Eli Lilly Expanded Gate Bioscience Partnership

The pharmaceutical giant increased its collaboration by $870 million to target additional protein-driven diseases.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration of a geometric sculptural protein channel, representing molecular-gate pharmaceutical research. — Eli Lilly has increased its partnership with Gate Bioscience by $870 million to further develop molecular-gate technology for treating protein-driven diseases. AI Illustration. Upload story photo >

Live Poll

Do you believe partnerships between big pharmaceutical companies and small biotech firms improve medical innovation?

Eli Lilly has expanded its existing partnership with Gate Bioscience by adding $870 million in potential milestone payments. The agreement adds a new drug target to their collaboration, which first began in 2025.

Why it matters

The deal signals deeper investment into cellular-level disease intervention, specifically targeting proteins that cause conditions such as prion disease. By scaling the collaboration, Eli Lilly increases its pipeline of potential treatments that block protein trafficking.

The partnership supports Gate Bioscience's proprietary molecular gates platform, which blocks disease-causing proteins inside the cell. It functions by targeting the SEC61 channel—a protein complex that acts as a gatekeeper for protein transport—to prevent faulty proteins from exiting the cell.

The players

Eli Lilly

A global pharmaceutical company with a pipeline focused on diabetes, oncology, and immunology.

Gate Bioscience

A biotechnology firm developing therapies that use molecular gates to block disease-causing proteins.

The details

Gate Bioscience utilizes molecular gates—small molecules designed to bind specific protein sequences—to interrupt cellular pathology. By obstructing the SEC61 channel, these molecules prevent proteins from being exported, effectively neutralizing them. This approach focuses on diseases where the output of malformed proteins is a primary driver of the clinical condition, such as prion disease.

2021: Gate Bioscience was founded.
2023: The company secured $60 million in series A financing.
2025: Eli Lilly and Gate Bioscience initiated their first partnership.
2025: Gate secured $65 million in series B financing, with Eli Lilly participating as an investor.

The Tech Race

This deal marks a significant commitment to intracellular protein modulation, placing Eli Lilly in direct competition with other firms investigating protein degradation and trafficking pathways. It represents a continuation of the strategy to secure early-stage platforms that can tackle previously 'undruggable' intracellular protein targets.

The agreement does not provide immediate consumer-facing products, as the collaboration remains in the research and development phase. Future clinical benefits will depend on the successful selection of drug targets and subsequent human trials.

The takeaway

This expansion demonstrates a shift toward controlling cellular protein traffic to treat degenerative conditions. Watch for the potential selection of a second drug target, which would trigger additional payments under the contract.